TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Discovery

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-12-0504PMID 23471820PMCID PMC3651770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

  2012cited by this paper
• Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

  2011cited by this paper
• JAK1 mutations are not frequent events in adult T‐ALL: a GRAALL study

  2010cited by this paper
• T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation.

  2010cited by this paper
• High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

  2009cited by this paper
• Janus kinases in immune cell signaling

  2009cited by this paper
• JAK 1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines

  2009cited by this paper
• RNAi screen for rapid therapeutic target identification in leukemia patients

  2009cited by this paper
• Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.

  2009cited by this paper
• T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

  2009cited by this paper
• JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines

  2009influential reference
• Molecular pathogenesis of T-cell leukaemia and lymphoma

  2008cited by this paper
• Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

  2008cited by this paper
• RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

  2008cited by this paper
• Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

  2008cited by this paper
• Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

  2008cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• Alu elements mediate MYB gene tandem duplication in human T-ALL

  2007cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• A loss-of-function RNA interference screen for molecular targets in cancer

  2006cited by this paper
• Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.

  2006cited by this paper
• The Consensus Coding Sequences of Human Breast and Colorectal Cancers

  2006cited by this paper
• Characterization of murine JAK2V617F-positive myeloproliferative disease.

  2006cited by this paper
• Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.

  2006cited by this paper
• Molecular genetics of acute lymphoblastic leukemia.

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• The role of BH3-only proteins in the immune system

  2005cited by this paper
• Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

  2003cited by this paper
• Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.

  2002influential reference
• Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation.

  2002cited by this paper
• Available from:

  2002cited by this paper
• Sensitization of IFN-γ Jak-STAT signaling during macrophage activation

  2002cited by this paper
• Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

  2001cited by this paper
• Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

  2001cited by this paper
• Interleukin-10 and the interleukin-10 receptor.

  2001cited by this paper
• Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.

  2000cited by this paper
• Partial impairment of cytokine responses in Tyk2-deficient mice.

  2000cited by this paper
• Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2

  1997cited by this paper
• Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

  1996cited by this paper
• Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells.

  1996cited by this paper
• The Janus protein tyrosine kinases in hematopoietic cytokine signaling.

  1995cited by this paper
• Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia

  1994cited by this paper
• bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes.

  1991cited by this paper

• A new heterozygous TYK2 gene mutation: Case report and review of the literature

  2025cites this paper
• Malignant JAK-signaling: at the interface of inflammation and malignant transformation

  2025cites this paper
• TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis

  2025cites this paper
• Developmental checkpoint targeting: Pre-TCR immunotherapy in leukemia and beyond.

  2025cites this paper
• Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

  2025cites this paper
• HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway

  2025cites this paper
• Review of Promising Off-Label Use of Deucravacitinib

  2025cites this paper
• Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia

  2025cites this paper
• Cancer-associated fibroblasts shape the formation of budding cancer cells at the invasive front of human colorectal cancer

  2025cites this paper
• CDK8/19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytes

  2024cites this paper
• MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors

  2023cites this paper
• Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling

  2023cites this paper
• Community analysis of large‐scale molecular dynamics simulations elucidated dynamics‐driven allostery in tyrosine kinase 2

  2023cites this paper
• Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches

  2023cites this paper
• Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia

  2022cites this paper
• The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion.

  2022cites this paper
• Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

  2022cites this paper
• Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma

  2022cites this paper
• Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia

  2022influential citation
• The Interaction Between Autophagy and JAK/STAT3 Signaling Pathway in Tumors

  2022cites this paper
• T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development

  2022cites this paper
• Tyk2 is a tumor suppressor in colorectal cancer

  2022cites this paper
• Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade

  2022cites this paper
• Regulation of activated T cell survival in rheumatic autoimmune diseases

  2022cites this paper
• Functional characterization of NPM1–TYK2 fusion oncogene

  2022cites this paper
• Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma

  2022cites this paper
• CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration

  2021cites this paper
• TYK2 in Cancer Metastases: Genomic and Proteomic Discovery

  2021influential citation
• Prognostic values and clinical relationship of TYK2 in laryngeal squamous cell cancer

  2021cites this paper
• Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma

  2021cites this paper
• Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway

  2021cites this paper
• Structural and mutational analysis of member-specific STAT functions.

  2021cites this paper
• The expression and the tumor suppressor role of CLDN6 in colon cancer

  2021cites this paper
• Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

  2021cites this paper
• Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

  2021cites this paper
• Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia

  2021cites this paper
• Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo

  2021cites this paper
• Janus Kinases in Leukemia

  2021cites this paper
• Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

  2021cites this paper
• Acute lymphoid leukemia etiopathogenesis

  2021cites this paper
• Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?

  2021cites this paper
• Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line.

  2020cites this paper
• Progress of JAK/STAT 3 and its inhibitors in the treatment of cancer

  2020cites this paper
• Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support

  2020cites this paper
• STAT1 and STAT3 are expressed in the human ovary and have JAK1-independent functions in the COV434 human granulosa cell line

  2020influential citation
• Cell Survival Failure in Effector T Cells From Patients With Systemic Lupus Erythematosus Following Insufficient Up‐Regulation of Cold‐Shock Y‐Box Binding Protein 1

  2020cites this paper
• TYK2 Variants in B-Acute Lymphoblastic Leukaemia

  2020influential citation
• IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells

  2020cites this paper
• Advances in germline predisposition to acute leukaemias and myeloid neoplasms

  2020cites this paper
• Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia

  2020cites this paper
• Epigenetic silencing of SOCS5 potentiates JAK‐STAT signaling and progression of T‐cell acute lymphoblastic leukemia

  2019cites this paper
• TYK2: An Upstream Kinase of STATs in Cancer

  2019influential citation
• The regulation of JAKs in cytokine signaling and its breakdown in disease.

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death

  2019cites this paper
• Efficacy of JAK1/2 and BCL2 inhibition on human T cell acute lymphoblastic leukemia in vitro and in vivo

  2019cites this paper
• New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia.

  2019cites this paper
• The ESCRT-Related ATPase Vps4 Is Modulated by Interferon during Herpes Simplex Virus 1 Infection

  2019cites this paper
• A critical regulator of Bcl2 revealed by systematic transcript discovery of lncRNAs associated with T-cell differentiation

  2019cites this paper
• Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders

  2019cites this paper
• An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery

  2019cites this paper
• The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL

  2019cites this paper
• Direct Targeting Options for STAT3 and STAT5 in Cancer

  2019cites this paper
• Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives

  2019cites this paper
• Activating mutations of the gp130/JAK/STAT pathway in human diseases.

  2019cites this paper
• Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma

  2018cites this paper
• Maintenance and Pharmacologic Targeting of ROR1 Protein Levels via UHRF1 in t(1;19) pre-B-ALL

  2018cites this paper
• Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

  2018cites this paper
• Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers

  2018cites this paper
• Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia

  2018cites this paper
• Genes at the Crossroad of Primary Immunodeficiencies and Cancer

  2018cites this paper
• RNAi screening of the tyrosine kinome in primary patient samples of acute myeloid leukemia

  2018cites this paper
• Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor

  2018cites this paper
• Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors

  2017cites this paper
• Targeted therapies for T‐cell acute lymphoblastic leukaemia (T‐ALL): what makes T‐ALL TYK?

  2017influential citation
• Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.

  2017cites this paper
• From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia.

  2017cites this paper
• Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia

  2017influential citation
• Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences

  2017cites this paper
• Drugging Transcription: Exploring Roles of CDK8 From Cancer to Immunity

  2017cites this paper
• Kinase Inhibitor Screening in Myeloid Malignancies.

  2017cites this paper
• The genetics and molecular biology of T-ALL.

  2017cites this paper
• Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation

  2017cites this paper
• CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

  2017cites this paper
• Vitamin D in hematological disorders and malignancies

  2017cites this paper
• Peptidomimetic blockade of MYB in acute myeloid leukemia

  2017cites this paper
• Stabilization of Notch1 by the Hsp90 Chaperone is Crucial for T-Cell Leukemogenesis

  2017cites this paper
• Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets

  2016cites this paper
• Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing

  2016cites this paper
• The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis

  2016cites this paper
• Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia.

  2016cites this paper
• Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains

  2016influential citation
• RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2

  2016cites this paper
• Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

  2016cites this paper
• RNAi Screening of Leukemia Cells Using Electroporation.

  2016cites this paper
• Development of Selective Covalent Janus Kinase 3 Inhibitors.

  2015cites this paper
• Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)*

  2015cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cites this paper